Trial Profile
Use of Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Aug 2023
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Immunodeficiency disorders; Inflammation
- Focus Adverse reactions; Proof of concept
- 07 Aug 2023 Planned End Date changed from 31 Oct 2023 to 31 Oct 2024.
- 07 Aug 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2024.
- 11 Oct 2019 Planned End Date changed from 31 Oct 2021 to 31 Oct 2023.